GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ALX Oncology Holdings Inc (NAS:ALXO) » Definitions » Degree of Operating Leverage

ALXO (ALX Oncology Holdings) Degree of Operating Leverage : 0.00 (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is ALX Oncology Holdings Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. ALX Oncology Holdings does not have enough data to calculate Degree of Operating Leverage.


ALX Oncology Holdings Degree of Operating Leverage Historical Data

The historical data trend for ALX Oncology Holdings's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ALX Oncology Holdings Degree of Operating Leverage Chart

ALX Oncology Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
Get a 7-Day Free Trial -1.69 - - - -

ALX Oncology Holdings Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ALX Oncology Holdings's Degree of Operating Leverage

For the Biotechnology subindustry, ALX Oncology Holdings's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ALX Oncology Holdings's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ALX Oncology Holdings's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where ALX Oncology Holdings's Degree of Operating Leverage falls into.


;
;

ALX Oncology Holdings Degree of Operating Leverage Calculation

ALX Oncology Holdings's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -128.315 (Mar. 2025) / -164.597 (Mar. 2024) - 1 )/( 0 (Mar. 2025) / 0 (Mar. 2024) - 1 )
=-0.2204/
=N/A***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


ALX Oncology Holdings  (NAS:ALXO) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


ALX Oncology Holdings Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of ALX Oncology Holdings's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


ALX Oncology Holdings Business Description

Traded in Other Exchanges
N/A
Address
323 Allerton Avenue, South San Francisco, CA, USA, 94080
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Executives
Shelly Pinto officer: VP, Finance and CAO 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Jaume Pons director, officer: President and CEO C/O ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Jason Lettmann director, 10 percent owner C/O RA PHARMACEUTICALS, INC., 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Rekha Hemrajani director 3928 POINT EDEN WAY, HAYWARD CA 94545
Sophia Randolph officer: Chief Medical Officer C/O ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Peter S Garcia officer: Chief Financial Officer ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
J. Scott Garland director 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Itziar Canamasas director C/O ALX ONCOLOGY HOLDINGS INC, 323 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
Lsv Associates, Llc 10 percent owner 2884 SAND HILL ROAD, SUITE 121, MENLO PARK CA 94025
G. Walmsley Graham director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Vivo Opportunity, Llc 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Goodman Corey S director, 10 percent owner, other: Executive Chairman 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Venbio Global Strategic Fund, L.p. 10 percent owner, other: See Remarks 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Steffen Pietzke officer: VP Fin & Chief Acct Officer C/O ENOVIX CORPORATION, 3501 W. WARREN AVENUE, FREMONT CA 94538
Vivo Opportunity Fund, L.p. 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301